Quidelortho Corpoation ($QDEL) Stock Forecast: Up 7.7% Today

What is Quidelortho Corpoation?

QuidelOrtho Corporation (QDEL) is a diagnostic company specializing in innovative health solutions that saw a strong bullish movement in the stock market recently.

Why is Quidelortho Corpoation going up?

QDEL stock is up 7.7% on Apr 30, 2026 18:11

• QuidelOrtho's price target was lowered by 18.10% to $29.38, indicating a revised outlook on the company's valuation. Despite this adjustment, the stock price rose by 6.1% to $12.29, demonstrating investor confidence.
• Vanguard revealed holding over 4 million shares of QDEL, signifying substantial passive investment in the company, potentially boosting market optimism.
• The recent completion of QuidelOrtho's acquisition of LEX Diagnostics for $100 million from TTP Group, coupled with FDA clearance for LEX's VELO molecular diagnostics platform, signals a strategic effort to fuel growth in the molecular diagnostics market. This acquisition likely influenced investor sentiment positively.
• The transfer of LEX Diagnostics from TTP Group to QuidelOrtho underscores the potential for expanding PCR technology and the synergy between the two companies, further enhancing market confidence in QDEL's future prospects.

QDEL Price Chart

QDEL Technical Analysis

QDEL News

QuidelOrtho (QDEL) price target decreased by 18.10% to 29.38

This article reports a significant decrease in QuidelOrtho's (QDEL) price target, which has been reduced by 18.10% to $29.38. This specific financial adjustment indicates a revised outlook on the company's valuation.

https://www.msn.com/en-us/money/topstocks/quidelortho-qdel-price-target-decreased-by-18-10-to-29-38/ar-AA21UOzE

Vanguard holds 4,088,168 shares of QuidelOrtho (NASDAQ: QDEL)

Vanguard Portfolio Management reported beneficial ownership of 4,088,168 shares, or 6%, of QuidelOrtho (NASDAQ: QDEL) common stock as of March 31, 2026. The filing, a Schedule 13G, indicates that Vanguard holds sole dispositive power over all these shares and sole voting power over 56,400 shares. This disclosure highlights Vanguard's significant but passive investment in the diagnostic company.

https://www.stocktitan.net/sec-filings/QDEL/schedule-13g-quidel-ortho-corp-passive-investment-disclosure-5-152a8a20d517.html

QuidelOrtho Corp (QDEL) Shares Surge 6.1% -- What GF Score of 60 Tells Investors

QuidelOrtho Corp (QDEL) shares surged 6.1% to $12.29. The stock is considered 69.0% undervalued based on its GF Value™ of $39.69, despite a GF Score™ of 60/100, which suggests above-average potential with concerns in financial strength and valuation. Insider buying activities further indicate a positive sentiment from executives.

https://www.gurufocus.com/news/8821356/quidelortho-corp-qdel-shares-surge-61-what-gf-score-of-60-tells-investors

QuidelOrtho completes $100m acquisition of LEX Diagnostics from TTP

QuidelOrtho Corporation has completed its $100 million acquisition of LEX Diagnostics from Cambridge-based TTP Group, following FDA clearance and CLIA waiver for LEX’s VELO molecular diagnostics platform in February 2026. The LEX VELO System provides rapid, highly sensitive RT-PCR testing for Influenza A, Influenza B, and COVID-19, supporting quick clinical decision-making at the point of care. This acquisition is a key step in QuidelOrtho's strategy to accelerate its growth in the molecular diagnostics market.

https://www.businessweekly.co.uk/posts/quidelortho-completes-100m-acquisition-of-lex-diagnostics-from-ttp

TTP Group sells LEX Diagnostics to QuidelOrtho to scale PCR tech

TTP Group has sold LEX Diagnostics, a company specializing in rapid PCR technology, to QuidelOrtho. This acquisition is expected to enable LEX Diagnostics to scale its innovative rapid PCR test for respiratory infections, benefiting from QuidelOrtho's established market presence in diagnostic solutions. The sale underscores the successful incubation and development of breakthrough health technologies by TTP Group.

http://www.msn.com/en-us/news/other/ttp-group-sells-lex-diagnostics-to-quidelortho-to-scale-pcr-tech/ar-AA21j7CR?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c

Trending Today

Binance Coin ($BNB) Crypto Forecast: Up 3.7% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

Quidelortho Corpoation Price History

21.03.2026 - QDEL Stock was down 5.3%

• The acquisition of LEX Diagnostics aimed to enhance QuidelOrtho's rapid molecular testing capabilities, focusing on point-of-care PCR testing for respiratory infections like Influenza A, B, and COVID-19.
• Analysts are optimistic about QuidelOrtho's potential return to profitability this year, however, the company preannounced weaker-than-expected first-quarter results due to market challenges and a soft respiratory season, leading to the bearish market movement.
• Market concerns about the soft respiratory season's impact on QuidelOrtho's financial performance may be overshadowing the long-term benefits of the acquisition of LEX Diagnostics and the expansion of its diagnostics portfolio.
• Investor caution regarding the company's ability to navigate market challenges and uncertainties is reflected in the downward trend of QDEL stock price, despite the strategic acquisition.

08.03.2026 - QDEL Stock was up 5.5%

• Despite a recent share price slump, QDEL experienced a strong bullish movement today.
• The significant undervaluation highlighted in the Discounted Cash Flow (DCF) analysis and the low Price-to-Sales (P/S) ratio could have attracted investors looking for a bargain.
• The trading down of 5.04% on April 6th might have triggered profit-taking by some investors, leading to a temporary dip in the stock price.
• The average price targets suggesting a "Hold" recommendation by Wall Street analysts and GuruFocus could have provided reassurance to investors, contributing to the bullish movement.

22.03.2026 - QDEL Stock was down 8.7%

• Possible reasons for the decline in QDEL's stock price include:
• QDEL announced weaker-than-anticipated first-quarter results despite acquiring LEX Diagnostics and their advanced VELO System, hinting at potential challenges in the existing market climate.
• The subdued respiratory season and various market obstacles highlighted in the earlier announcement may have influenced investor confidence and contributed to the stock's depreciation.
• Concerns about how smoothly LEX Diagnostics will be integrated into QDEL's operations and the effectiveness of leveraging the new molecular testing platform are likely impacting investor decisions.
• The stock's proximity to its lowest point in the past 52 weeks before the acquisition could also be influencing market sentiment, leading investors to await tangible outcomes from the acquisition to restore faith in QDEL's future growth opportunities.

07.03.2026 - QDEL Stock was down 6.5%

• Market sentiment shifted negatively, with the 5.04% drop in QDEL shares suggesting a lack of short-term investor confidence.
• Despite potential upside predicted by analysts and GuruFocus, the day's low of $16.20 and closing at $16.38 indicate ongoing market uncertainties.
• The bearish movement could be attributed to profit-taking, broader market conditions, or undisclosed company-specific factors.
• Investors are likely monitoring future developments and company updates to assess QDEL's performance in the upcoming days.

30.03.2026 - QDEL Stock was up 5.6%

• A noteworthy passive investment from Vanguard in QuidelOrtho indicates strong investor confidence in the company's future prospects, contributing to the bullish trend.
• The rise in QDEL shares is linked to its undervaluation according to its GF Value™, complemented by positive insider buying signals from executives.
• QuidelOrtho's acquisition of LEX Diagnostics for $100 million and obtaining FDA clearance for its VELO molecular diagnostics platform demonstrate the company's dedication to expanding its presence in the molecular diagnostics sector, fueling investor optimism.
• The acquisition of LEX Diagnostics by QuidelOrtho from TTP Group highlights the growth potential and innovation in rapid PCR technology, solidifying QuidelOrtho's market position and driving the positive movement in the stock.

30.03.2026 - QDEL Stock was up 7.7%

• QuidelOrtho's price target was lowered by 18.10% to $29.38, indicating a revised outlook on the company's valuation. Despite this adjustment, the stock price rose by 6.1% to $12.29, demonstrating investor confidence.
• Vanguard revealed holding over 4 million shares of QDEL, signifying substantial passive investment in the company, potentially boosting market optimism.
• The recent completion of QuidelOrtho's acquisition of LEX Diagnostics for $100 million from TTP Group, coupled with FDA clearance for LEX's VELO molecular diagnostics platform, signals a strategic effort to fuel growth in the molecular diagnostics market. This acquisition likely influenced investor sentiment positively.
• The transfer of LEX Diagnostics from TTP Group to QuidelOrtho underscores the potential for expanding PCR technology and the synergy between the two companies, further enhancing market confidence in QDEL's future prospects.

16.03.2026 - QDEL Stock was down 33.1%

• QuidelOrtho (QDEL) disclosed a revenue decrease for Q1 2026, attributing it to a slow respiratory season and subdued international sales, particularly in China.
• The company expects negative free cash flow for Q1 2026, largely stemming from market difficulties and delayed orders in the EMEA region.
• Despite the underwhelming financial outcomes, QuidelOrtho expresses confidence in meeting the lower end of its full-year 2026 financial projections, stressing the resilience of its core operations and cost-saving strategies in place.
• The bearish trend in QDEL's market performance is linked to the soft revenue forecast for Q1 2026, sparking investor worries about the company's near-term financial health.

23.03.2026 - QDEL Stock was down 8.3%

• Following the acquisition of LEX Diagnostics, QuidelOrtho saw a decrease in its stock performance.
• The drop in QDEL's stock value is possibly connected to the company announcing lower-than-anticipated first-quarter results due to a mild respiratory season and various market obstacles.
• Investors seem worried about the immediate financial effects on QuidelOrtho, resulting in a selloff of the stock despite the growth possibilities from the acquisition.
• The market appears to be adopting a careful stance, observing how QuidelOrtho will utilize the recent acquisition to boost its revenue and profitability in the upcoming quarters.

17.03.2026 - QDEL Stock was up 5.5%

• QDEL stock experienced a notable gain today, despite a recent 27.5% drop, leading to a year-to-date decline of 55.6%.
• Insiders purchased $0.6 million worth of shares, indicating confidence in the company's future prospects.
• Despite financial hurdles like a high debt-equity ratio and consecutive quarters of negative results, the temporary rise in stock price might be influenced by technical indicators showing a mixed picture, with some signals leaning towards bullish.
• Analyst sentiment has been mostly pessimistic, with downgrades and price target decreases, but recent insider transactions of acquiring additional shares by key personnel may have sparked optimism among investors, contributing to the bullish movement.

13.03.2026 - QDEL Stock was up 5.8%

• Despite a price target cut by UBS, Quidel's stock showed strong bullish movement, suggesting market resilience.
• The partnership with Lifotronic Technology to enhance its immunoassay portfolio possibly increased investor confidence in Quidel's growth prospects.
• Concerns arose over the impact of proposed NIH funding cuts on the demand for diagnostic solutions, contributing to a recent stock decline.
• Amid challenges in healthcare funding, Quidel's focus on non-respiratory business growth and international expansion may drive future performance.

15.03.2026 - QDEL Stock was up 6.5%

• Quidel's shares saw a 7.7% surge, showcasing a positive shift despite a previous decline from its yearly high, demonstrating growing investor confidence in the company.
• A strategic supply agreement with Lifotronic Technology to enhance its immunoassay portfolio reflects optimism about Quidel's global market competitiveness and product range.
• Concerns arose due to proposed cuts in NIH funding, causing a significant 18.0% decrease in Quidel's shares, underscoring the influence of healthcare funding policies on investor perceptions and company performance.
• Despite obstacles like reduced COVID testing revenues and organizational adjustments, Quidel's insider purchases and new partnerships indicate proactive efforts to navigate market uncertainties and propel future expansion.

29.03.2026 - QDEL Stock was down 5.2%

• Today's downward movement in QDEL's stock price may be due to investors selling off shares to lock in profits following a recent uptrend.
• Concerns over integration challenges and the potential benefits of the $100 million acquisition of LEX Diagnostics from TTP Group could be contributing to the stock's decline.
• Reports of routine equity compensation activities by QDEL's COO may have sparked uncertainty among investors about the company's financial management strategies.
• Although informative, the released podcast episode by QuidelOrtho on syphilis trends is unlikely to have directly influenced today's stock performance.